• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受根治性前列腺切除术且符合主动监测条件的老年患者中,分期升级和上调的发生率更高。

Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillance.

作者信息

Busch Jonas, Magheli Ahmed, Leva Natalia, Ferrari Michelle, Kramer Juergen, Klopf Christian, Kempkensteffen Carsten, Miller Kurt, Brooks James D, Gonzalgo Mark L

机构信息

Department of Urology, Charité University Medicine, Berlin, Germany.

出版信息

BJU Int. 2014 Oct;114(4):517-21. doi: 10.1111/bju.12466. Epub 2014 Jan 22.

DOI:10.1111/bju.12466
PMID:24112652
Abstract

OBJECTIVE

To determine pathological and oncological outcomes of patients diagnosed with low-risk prostate cancer in two age cohorts who underwent radical prostatectomy (RP) and qualified for active surveillance (AS) according to Prostate Cancer Research International: Active Surveillance (PRIAS) criteria, as AS for low-risk prostate cancer represents an acceptable management strategy especially for older patients.

PATIENTS AND METHODS

In all, 320 patients aged ≥65 years who underwent RP and were eligible for AS according to PRIAS criteria were propensity score matched 1:1 to patients aged <65 years. Patient characteristics were compared with chi-square, Kruskal-Wallis, and one-way anova tests. Predictors of RP pathological upgrading or upstaging were analysed using logistic regression. Recurrence-free survival (RFS) and overall survival (OS) were calculated using the Kaplan-Meier method. Predictors of RFS were analysed within Cox regression models.

RESULTS

Pathological upgrading and upstaging were significantly higher among older (≥65 years) vs younger (<65 years) patients (53.1% vs 44.1% and 12.2% vs 7.2%, respectively). Higher prostate-specific antigen levels and increasing age were independent predictors of upgrading among patients aged <65 years. There were no differences in RFS or OS between the two age groups. Positive surgical margin status was the only independent predictor of shorter RFS.

CONCLUSIONS

Patients aged ≥65 years who are eligible for AS by PRIAS criteria have a higher risk of being upgraded and upstaged at RP than those aged <65 years. These findings should be taken into consideration when discussing treatment options for patients diagnosed with prostate cancer.

摘要

目的

根据国际前列腺癌研究组织:主动监测(PRIAS)标准,确定两个年龄队列中被诊断为低风险前列腺癌且接受了根治性前列腺切除术(RP)并符合主动监测(AS)条件的患者的病理和肿瘤学结局,因为低风险前列腺癌的主动监测是一种可接受的管理策略,尤其对于老年患者。

患者与方法

总共320例年龄≥65岁且接受了RP并根据PRIAS标准符合主动监测条件的患者,按倾向评分1:1与年龄<65岁的患者进行匹配。使用卡方检验、Kruskal-Wallis检验和单因素方差分析对患者特征进行比较。使用逻辑回归分析RP病理升级或分期上升的预测因素。采用Kaplan-Meier法计算无复发生存期(RFS)和总生存期(OS)。在Cox回归模型中分析RFS的预测因素。

结果

老年(≥65岁)患者的病理升级和分期上升显著高于年轻(<65岁)患者(分别为53.1%对44.1%和12.2%对7.2%)。年龄<65岁的患者中,较高的前列腺特异性抗原水平和年龄增长是升级的独立预测因素。两个年龄组之间的RFS或OS无差异。手术切缘阳性状态是RFS较短的唯一独立预测因素。

结论

根据PRIAS标准符合主动监测条件的≥65岁患者在RP时发生升级和分期上升的风险高于<65岁的患者。在讨论前列腺癌诊断患者的治疗方案时应考虑这些发现。

相似文献

1
Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillance.接受根治性前列腺切除术且符合主动监测条件的老年患者中,分期升级和上调的发生率更高。
BJU Int. 2014 Oct;114(4):517-21. doi: 10.1111/bju.12466. Epub 2014 Jan 22.
2
Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.低危前列腺癌患者符合前列腺癌国际主动监测标准行根治性前列腺切除术的病理和生化结局。
BJU Int. 2013 May;111(6):914-20. doi: 10.1111/j.1464-410X.2012.11658.x. Epub 2013 Jan 15.
3
Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS).适合主动监测的前列腺癌根治术患者的结局分析(PRIAS)。
BJU Int. 2013 Jan;111(1):53-9. doi: 10.1111/j.1464-410X.2012.11276.x. Epub 2012 Jun 21.
4
Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.根治性前列腺切除术是治疗标本中存在高病理 Gleason 评分前列腺癌的有效方法。
BJU Int. 2013 May;111(5):723-30. doi: 10.1111/j.1464-410X.2012.11114.x. Epub 2012 Apr 4.
5
The Impact of Prostate Cancer Upgrading and Upstaging on Biochemical Recurrence and Cancer-Specific Survival.前列腺癌升级和升期对生化复发和癌症特异性生存的影响。
Medicina (Kaunas). 2020 Feb 4;56(2):61. doi: 10.3390/medicina56020061.
6
Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series.根治性前列腺切除术后 Gleason 评分升级的临床和病理预测因素:单机构系列研究结果。
Urol Oncol. 2011 Sep-Oct;29(5):508-14. doi: 10.1016/j.urolonc.2009.07.003. Epub 2009 Oct 17.
7
Tumour characteristics, oncological and functional outcomes in patients aged ≥ 70 years undergoing radical prostatectomy.≥70 岁患者行根治性前列腺切除术的肿瘤特征、肿瘤学和功能结局。
BJU Int. 2013 Mar;111(3 Pt B):E24-9. doi: 10.1111/j.1464-410X.2012.11368.x. Epub 2012 Sep 5.
8
Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.根治性前列腺切除术改善了 PSA 时代淋巴结阳性前列腺癌男性的无进展生存期和癌症特异性生存期:一项确认性研究。
BJU Int. 2011 Jun;107(11):1755-61. doi: 10.1111/j.1464-410X.2010.09730.x. Epub 2010 Oct 13.
9
Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.基于当代多核心前列腺活检的前列腺特异性抗原与前列腺特异性抗原密度对诊断为 Gleason 6 前列腺癌患者升级的预测作用。
BJU Int. 2012 Dec;110(11 Pt B):E494-9. doi: 10.1111/j.1464-410X.2012.11182.x. Epub 2012 Apr 30.
10
Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.基于人群的研究:预测前列腺癌 Gleason6 评分患者主动监测不良病理的因素。
J Urol. 2014 Feb;191(2):350-7. doi: 10.1016/j.juro.2013.09.034. Epub 2013 Sep 23.

引用本文的文献

1
The Older the Patients, the More Aggressive the Prostate Cancer Detected Even Among Those With a Prostate-Specific Antigen Level Below the Low-Risk Threshold: Analysis Using Nationwide Korean Data.患者年龄越大,即便前列腺特异性抗原水平低于低风险阈值,所检测出的前列腺癌侵袭性越强:基于韩国全国数据的分析
J Korean Med Sci. 2025 Apr 21;40(15):e57. doi: 10.3346/jkms.2025.40.e57.
2
Comparing histology between prostate cognitive fusion targeted biopsy and radical prostatectomy: exploring risk factors of Gleason score upgrading in Chinese patients.对比前列腺认知融合靶向活检和根治性前列腺切除术的组织学表现:探究中国患者 Gleason 评分升级的风险因素。
J Cancer Res Clin Oncol. 2023 Dec;149(20):18029-18037. doi: 10.1007/s00432-023-05506-3. Epub 2023 Nov 18.
3
The Challenges of Patient Selection for Prostate Cancer Focal Therapy: A Retrospective Observational Multicentre Study.前列腺癌局部治疗中患者选择的挑战:一项回顾性观察性多中心研究。
Curr Oncol. 2022 Sep 22;29(10):6826-6833. doi: 10.3390/curroncol29100538.
4
Differences in Prostate Cancer Transcriptomes by Age at Diagnosis: Are Primary Tumors from Older Men Inherently Different?前列腺癌转录组学的年龄差异:老年男性的原发肿瘤是否存在固有差异?
Cancer Prev Res (Phila). 2022 Dec 1;15(12):815-825. doi: 10.1158/1940-6207.CAPR-22-0212.
5
Prostate Cancer Biomarker Development: National Cancer Institute's Early Detection Research Network Prostate Cancer Collaborative Group Review.前列腺癌生物标志物的开发:美国国家癌症研究所早期检测研究网络前列腺癌协作组综述。
Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2454-2462. doi: 10.1158/1055-9965.EPI-20-1104. Epub 2020 Oct 22.
6
Prediction of pathologic upgrading in Gleason score 3+4 prostate cancer: Who is a candidate for active surveillance?预测 Gleason 评分 3+4 前列腺癌中的病理性升级:哪些患者适合主动监测?
Investig Clin Urol. 2020 Jul;61(4):405-410. doi: 10.4111/icu.2020.61.4.405. Epub 2020 May 25.
7
New Biopsy Techniques and Imaging Features of Transrectal Ultrasound for Targeting PI-RADS 4 and 5 Lesions.经直肠超声针对PI-RADS 4和5类病变的新型活检技术及影像特征
J Clin Med. 2020 Feb 15;9(2):530. doi: 10.3390/jcm9020530.
8
Effects of pathological upstaging or upgrading on metastasis and cancer-specific mortality in men with clinical low-risk prostate cancer.临床低危前列腺癌患者病理性升级或分期升级对转移和癌症特异性死亡的影响。
BJU Int. 2018 Dec;122(6):1003-1009. doi: 10.1111/bju.14418. Epub 2018 Jun 22.
9
Outcomes of patients older than 75 years with non-metastatic prostate cancer.75岁以上非转移性前列腺癌患者的治疗结果
Asian J Urol. 2017 Apr;4(2):102-106. doi: 10.1016/j.ajur.2016.12.001. Epub 2017 Jan 3.
10
Comparative rates of upstaging and upgrading in Caucasian and Korean prostate cancer patients eligible for active surveillance.符合主动监测条件的白种人和韩国前列腺癌患者分期上调和分级上调的比较率
PLoS One. 2017 Nov 14;12(11):e0186026. doi: 10.1371/journal.pone.0186026. eCollection 2017.